Commentary: Outcome measures were flawed.
Ebers
G C
GC
University of Oxford, John Radcliffe Hospital, Oxford OX39DU. George.Ebers@clneuro.ox.ac.uk
D003362:Cost-Benefit Analysis; D003625:Data Collection; D016527:Drug Costs; D000068717:Glatiramer Acetate; D006297:Health Services Accessibility / Q000191:economics / Q000458:organization & administration*; D006801:Humans; D007372:Interferons / Q000191:economics / Q000600:supply & distribution; D009682:Magnetic Resonance Spectroscopy; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000191:economics; D017063:Outcome Assessment, Health Care; D010455:Peptides / Q000191:economics / Q000600:supply & distribution; D020414:Risk Sharing, Financial
D010455:Peptides; D000068717:Glatiramer Acetate; D007372:Interferons